cilgavimab
Trade name: Evushield
mAbexperimentalCOVID-19
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
2
Phase 4
1
Earliest trial started Mar 16, 2021 (NCT04896541)
Timeline
Indications
Approved for
Mechanism of action
- Tumor antigensANTAGONIST
Tumor antigens antagonist
- Spike glycoproteinBLOCKER
Spike glycoprotein blocker
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650258 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05587894 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2022 | Government of France, University of Geneva |
| NCT05982704 | Phase 4 | Aug 18, 2022 | Government of Russia |
| NCT05375760 | Phase 2 | Jun 9, 2022 | AstraZeneca |
| NCT05321394 | Phase 3 | Mar 7, 2022 | Agenzia Italiana del Farmaco, University of Udine, University of Verona |
| NCT05166421 | Phase 1 | Nov 30, 2021 | AstraZeneca |
| NCT04896541 | Phase 1 | Mar 16, 2021 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2021 |
| Agenzia Italiana del Farmaco | Government | 1 | 0 | 1 | 2022 |
| Government of France | Government | 1 | 1 | 1 | 2022 |
| Government of Russia | Government | 1 | 1 | 1 | 2022 |
| University of Geneva | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Udine | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Verona | Academic/Hospital | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1